Traders Purchase High Volume of Eyepoint Pharmaceuticals Call Options (NASDAQ:EYPT)

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the recipient of unusually large options trading on Tuesday. Stock traders acquired 3,011 call options on the company. This is an increase of approximately 19% compared to the typical volume of 2,531 call options.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EYPT. KBC Group NV purchased a new position in shares of Eyepoint Pharmaceuticals during the first quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after acquiring an additional 1,358 shares during the period. Russell Investments Group Ltd. bought a new position in Eyepoint Pharmaceuticals during the third quarter valued at approximately $76,000. Tower Research Capital LLC TRC increased its position in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Stock Performance

Shares of Eyepoint Pharmaceuticals stock traded up $0.54 on Tuesday, reaching $5.41. 9,578,367 shares of the stock were exchanged, compared to its average volume of 1,679,924. The firm has a market cap of $466.40 million, a PE ratio of -1.44 and a beta of 1.76. The firm’s 50 day moving average is $13.10 and its 200-day moving average is $13.62. Eyepoint Pharmaceuticals has a one year low of $3.95 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. On average, equities research analysts expect that Eyepoint Pharmaceuticals will post -3.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EYPT has been the topic of several recent research reports. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $5.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. Chardan Capital reissued a “neutral” rating and set a $5.00 target price on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals has a consensus rating of “Hold” and an average price target of $28.11.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: DURAVYU was reported as non-inferior to aflibercept in an ad hoc analysis that excluded an asymmetric group of nine patients whose vision loss was considered unrelated to wet AMD. The company also highlighted a 42% reduction in treatment burden, favorable safety with redosing, strong anatomic control, and other supportive secondary endpoints. EyePoint LUGANO trial results
• Positive Sentiment: Jefferies maintained a “buy” rating while lowering its price target to $8, implying substantial upside from recent trading levels. Chardan also previously maintained a bullish rating, although its latest view has changed.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the clinical-trial results were released, reflecting the market significance of the announcement.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating, while JPMorgan reaffirmed its neutral view. Chardan Capital and RBC also reaffirmed neutral or sector-perform ratings, each assigning a $5 price target.
• Negative Sentiment: The full LUGANO dataset did not achieve the trial’s primary endpoint, a major setback for DURAVYU’s regulatory and commercial prospects. The company may need to explain the impact of the vision-loss cohort and how the remaining Phase 3 program will proceed. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral,” while multiple analysts have reduced or reaffirmed cautious price targets. Investor discussion has also shifted toward competing ophthalmology companies as potentially stronger opportunities.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.